3 Phosphoinositide Dependent Protein Kinase 1 Market Trends, Size, Competitive Analysis and Forecast 2021-2027
The global 3 phosphoinositide dependent protein kinase 1 market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). PDK1 or 3-Phosphoinositide-dependent kinase 1 is a key member of the AGC protein kinase family and is important in a variety of cellular functions which leads to the activation of the PI3K signalling pathway which is an event that is associated with the onset and progression of several human cancers. The major factor contributing to the growth of the market is the increasing prevalence of breast cancer across the globe.
According to the World Health
Organization (WHO), breast cancer is the globe’s most prevalent cancer.
Additionally, there were 2.3 million women diagnosed with breast cancer with a
mortality rate of 685,000 globally in 2020. Furthermore, as of December 2020,
there were 7.8 million women alive while being diagnosed with breast cancer in
the past 5 years. Hence, the increasing prevalence of this disease is driving
the growth of the global 3 phosphoinositide dependent protein kinase 1 market.
To Request a Sample of our Report on 3 Phosphoinositide
Dependent Protein Kinase 1 Market:
https://www.omrglobal.com/request-sample/3-phosphoinositide-dependent-protein-kinase-1-market
Some major players operating in
the market include Boehringer Ingelheim GmbH, among others. The market players
are contributing significantly to the growth of the market by the adoption of
various strategies including mergers & acquisitions, geographical
expansion, partnerships and collaborations, and new product launches, to stay
competitive in the market. For instance, in May 2019, Novartis announced the
approval of Piqray (alpelisib) tablets from the US FDA. It is used in
combination with the endocrine therapy fulvestrant for the treatment of
postmenopausal women, and men, with hormone receptor (HR)-positive, human
epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or
metastatic breast cancer.
Market Coverage
• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
Segment Covered-
·
By Type
·
By Application
Regions Covered-
·
North America
·
Europe
·
Asia-Pacific
·
Rest of the World
Competitive Landscape-
Boehringer Ingelheim GmbH, AstraZeneca plc, and Bayer AG, among others.
(Get 15% Discount on Buying this Report)
A
full Report of 3 Phosphoinositide Dependent Protein Kinase 1 Market is
Available @ https://www.omrglobal.com/industry-reports/3-phosphoinositide-dependent-protein-kinase-1-market
Global 3 Phosphoinositide Dependent Protein Kinase 1
Market Report by Segment
By Type
• HCI-1708
• AR-12
• PHT-427
• SNS-229
• Others
By Application
• Clinic
• Hospital
• Others
Global 3 Phosphoinositide Dependent Protein Kinase 1
Market Report by Region
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Spain
·
France
·
Italy
·
Rest of Europe
Asia-Pacific
·
India
·
China
·
Japan
·
South Korea
·
Rest of APAC
Rest of the World
·
Latin America
·
Middle East & Africa
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company
known for its crisp and concise reports. The company is equipped with an
experienced team of analysts and consultants. OMR offers quality syndicated
research reports, customized research reports, consulting and other
research-based services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment